Cambiando entre el inhibidor de Janus quinasa upadacitinib y adalimumab siguiendo respuesta insuficiente: eficacia y seguridad en pacientes con artritis reumatoide
Ann Rheum Dis 2020; doi:10.1136/annrheumdis-2020-21841220
View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
Ann Rheum Dis 2020; doi:10.1136/annrheumdis-2020-21841220
Ann Rheum Dis 2020 DOI:10.1136/annrheumdis-2020-218510
Arthritis Care Res (Hoboken) 2020;72(8):1112-1121
Clin Exp Rheumatol . Jul-Aug 2020;38(4):732-741. Epub 2020 May 20.
Clin Exp Rheumatol . Sep-Oct 2020;38(5):848-857. Epub 2019 Dec 19.
Arthritis Rheumatol. 2019 Jun;71(6):878-891
J Rheumatol 2018 Feb; 45(2):177-87
Arthritis Res Ther. 2017 Sep 18;19(1):208
Arthritis Rheumatol 2016. DOI 10.1002/art.39953. Accepted article
Annals of the Rheumatic Diseases. 2015 Aug 14. doi:pii: annrheumdis-2014-207178.